Holen Sie sich die Stockscreener-App
85.69
1.61%
-1.40
Handel nachbörslich:
85.69
Schlusskurs vom Vortag:
$87.09
Offen:
$88.1
24-Stunden-Volumen:
560.05K
Relative Volume:
0.45
Marktkapitalisierung:
$7.56B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-36.34
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
-5.05%
1M Leistung:
-20.18%
6M Leistung:
+87.59%
1J Leistung:
+448.94%
1-Tages-Spanne:
$85.63
$88.10
1-Wochen-Bereich:
$82.93
$94.06
52-Wochen-Spanne:
$15.49
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
85.69 | 7.56B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Cameron Turtle: The $1.6 Billion Bet That IBD's 25% Ceiling Is About to Break - finance.biggo.com
Spyre Therapeutics at Stifel forum: betting on autoimmune combinations By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis? - finance.yahoo.com
Spyre Therapeutics, Inc Income Statement – MUN:3920 - TradingView
Equity in earnings of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: A Biotech Stock with a Potential 29.56% Upside - DirectorsTalk Interviews
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests - finance.yahoo.com
Spyre Therapeutics, Inc Statistics – GETTEX:3920 - TradingView
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90 - Stock Titan
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - finance.yahoo.com
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - Sahm
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade) - Seeking Alpha
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - TradingView
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):